Rezolute (RZLT) Common Equity (2010 - 2026)
Rezolute recorded quarterly Common Equity of $116.8 million in Q1 2026, down 8.72% quarter-over-quarter from $128.0 million in Q4 2025, and up 41.5% year-over-year from $82.6 million in Q1 2025.
Rezolute's Common Equity history runs 17 years deep, the most recent figure standing at $116.8 million for Q1 2026.
- In Q1 2026, Common Equity rose 41.5% year-over-year to $116.8 million; the TTM figure through Mar 2026 stood at $116.8 million (up 41.5% YoY), while the FY2025 annual figure was $162.1 million, up 33.99% from the prior year.
- Common Equity came in at $116.8 million for Q1 2026 at Rezolute, down from $128.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $162.1 million in Q2 2025 to a low of $51.9 million in Q1 2022.
- A 5-year average of $116.2 million and a median of $116.8 million in 2026 frame the typical range for Common Equity.
- Across the five-year window, Common Equity surged 610.1% in 2022 and slumped 44.34% in 2024, its largest moves.
- Rezolute's Common Equity stood at $141.3 million in 2022, then tumbled by 35.07% to $91.7 million in 2023, then advanced by 8.57% to $99.6 million in 2024, then grew by 28.53% to $128.0 million in 2025, then declined by 8.72% to $116.8 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $116.8 million, $128.0 million, and $147.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 116.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116.83 Mn |
| Dec 31, 2025 | 128.00 Mn |
| Sep 30, 2025 | 147.17 Mn |
| Jun 30, 2025 | 162.13 Mn |
| Mar 31, 2025 | 82.57 Mn |
| Dec 31, 2024 | 99.59 Mn |
| Sep 30, 2024 | 113.44 Mn |
| Jun 30, 2024 | 121.00 Mn |
| Mar 31, 2024 | 70.86 Mn |
| Dec 31, 2023 | 91.73 Mn |
| Sep 30, 2023 | 103.56 Mn |
| Jun 30, 2023 | 116.17 Mn |
| Mar 31, 2023 | 127.32 Mn |
| Dec 31, 2022 | 141.27 Mn |
| Sep 30, 2022 | 153.09 Mn |
| Jun 30, 2022 | 149.47 Mn |
| Mar 31, 2022 | 51.91 Mn |
| Dec 31, 2021 | 62.27 Mn |
| Sep 30, 2021 | 21.56 Mn |
| Jun 30, 2021 | 26.10 Mn |
| Mar 31, 2021 | 29.13 Mn |
| Dec 31, 2020 | 35.89 Mn |
| Sep 30, 2020 | 4.38 Mn |
| Jun 30, 2020 | 7.37 Mn |
| Mar 31, 2020 | 10.33 Mn |
| Dec 31, 2019 | 14.69 Mn |
| Sep 30, 2019 | 20.62 Mn |
| Jun 30, 2019 | 1.75 Mn |
| Mar 31, 2019 | 4.65 Mn |
| Dec 31, 2018 | -9.79 Mn |
| Sep 30, 2018 | -6.44 Mn |
| Jun 30, 2018 | -3.96 Mn |
| Mar 31, 2018 | 532,930.00 |
| Dec 31, 2017 | 3.80 Mn |
| Sep 30, 2017 | 7.81 Mn |
| Jun 30, 2017 | 8.53 Mn |
| Mar 31, 2017 | 8.46 Mn |
| Dec 31, 2016 | 7.93 Mn |
| Sep 30, 2016 | 8.20 Mn |
| Jun 30, 2016 | 8.77 Mn |
| Mar 31, 2016 | 1.12 Mn |
| Dec 31, 2015 | 3.78 Mn |
| Sep 30, 2015 | 6.76 Mn |
| Jun 30, 2015 | 9.05 Mn |
| Mar 31, 2015 | 9.70 Mn |
| Dec 31, 2014 | 7.82 Mn |
| Sep 30, 2014 | 5.02 Mn |
| Jun 30, 2014 | 6.41 Mn |
| Mar 31, 2014 | 3.41 Mn |
| Dec 31, 2013 | -4.40 Mn |
| Sep 30, 2013 | -4.82 Mn |
| Jun 30, 2013 | -4.16 Mn |
| Mar 31, 2013 | -3.55 Mn |
| Dec 31, 2012 | -24,470.00 |
| Sep 30, 2012 | -15,163.00 |
| Jun 30, 2012 | -1.29 Mn |
| Mar 31, 2012 | 36.00 |
| Dec 31, 2011 | -890,704.00 |
| Sep 30, 2011 | 17,979.00 |
| Jun 30, 2011 | -505,530.00 |
| Dec 31, 2010 | -300,489.00 |